Replies to post #87379 on Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

Last Q&A of Ken Berlin is that they think AIM2CERV becomes a significant partner able asset after initial readout...

No. That's not what he said. He said something along the lines of "We think this data timeline will make this a more partnerable asset," indicating to me that they feel that a shortened timeline will de-risk the platform for partnerships. That means we're in play immediately after we hear from the FDA.